PCSK9 Inhibitor Therapeutics 2018: Analyses of Specific Patient Populations Data is organized by AcademicCME and will be held during Apr 16, 2018 - Apr 15, 2019.
The target audience for this medical event is Cardiologists, internists, nurse practitioners, nurses and other healthcare professionals involved in the management of patients with dyslipidemia. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credit.
This educational program will explore and analyze data for PCSK9 inhibitor therapeutics in specific patient populations. Expert faculty will relay updates regarding recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at high CV risk.
• Explain the most recent subset data for outcomes trials concerning PCSK9 inhibitors
• Apply recent dyslipidemia guidelines and optimal PCSK9 inhibitors into clinical practice
• Incorporate recent PCSK9 inhibitor data to improve outcomes for dyslipidemia patients with stroke or at high CV risk
• Discuss strategies to improve knowledge, skills, or performance of the healthcare team
Additional details will be posted as soon as they are available.